TY - JOUR
T1 - Recent progress toward the implementation of phage therapy in Western medicine
AU - Pirnay, Jean Paul
AU - Ferry, Tristan
AU - Resch, Grégory
N1 - Publisher Copyright:
© 2021 The Author(s) 2021. Published by Oxford University Press on behalf of FEMS. All rights reserved. For permissions, please e-mail: [email protected].
PY - 2022/1/1
Y1 - 2022/1/1
N2 - Like the sword of Damocles, the threat of a post-antibiotic era is hanging over humanity's head. The scientific and medical community is thus reconsidering bacteriophage therapy (BT) as a partial but realistic solution for treatment of difficult-to-eradicate bacterial infections. Here, we summarize the latest developments in clinical BT applications, with a focus on developments in the following areas: (i) pharmacology of bacteriophages of major clinical importance and their synergy with antibiotics; (ii) production of therapeutic phages; and (iii) clinical trials, case studies and case reports in the field. We address regulatory concerns, which are of paramount importance insofar as they dictate the conduct of clinical trials, which are needed for broader BT application. The increasing amount of new available data confirms the particularities of BT as being innovative and highly personalized. The current circumstances suggest that the immediate future of BT may be advanced within the framework of national BT centers in collaboration with competent authorities, which are urged to adopt incisive initiatives originally launched by some national regulatory authorities.
AB - Like the sword of Damocles, the threat of a post-antibiotic era is hanging over humanity's head. The scientific and medical community is thus reconsidering bacteriophage therapy (BT) as a partial but realistic solution for treatment of difficult-to-eradicate bacterial infections. Here, we summarize the latest developments in clinical BT applications, with a focus on developments in the following areas: (i) pharmacology of bacteriophages of major clinical importance and their synergy with antibiotics; (ii) production of therapeutic phages; and (iii) clinical trials, case studies and case reports in the field. We address regulatory concerns, which are of paramount importance insofar as they dictate the conduct of clinical trials, which are needed for broader BT application. The increasing amount of new available data confirms the particularities of BT as being innovative and highly personalized. The current circumstances suggest that the immediate future of BT may be advanced within the framework of national BT centers in collaboration with competent authorities, which are urged to adopt incisive initiatives originally launched by some national regulatory authorities.
KW - PK/PD
KW - antibiotic resistance
KW - bacterial virus
KW - bacteriophage
KW - multirug resistance
KW - phage therapy
UR - http://www.scopus.com/inward/record.url?scp=85123808558&partnerID=8YFLogxK
U2 - 10.1093/femsre/fuab040
DO - 10.1093/femsre/fuab040
M3 - Review article
C2 - 34289033
AN - SCOPUS:85123808558
SN - 0168-6445
VL - 46
JO - FEMS Microbiology Reviews
JF - FEMS Microbiology Reviews
IS - 1
M1 - fuab040
ER -